ClinicalTrials.gg

Program

atogepant

Also written as “Atogepant”, “Atogepant 60 mg” and “Atogepant 30 mg”.

Its studies are mostly in Migraine Disorders, led by AbbVie.

Furthest: phase 4, since Feb 22, 202219 company-led studies, 4 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie194 open or runningphase 4since Feb 22, 2022Jul 26, 2016Mar 2028phase 3 · NCT05711394

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 26, 2016.

  1. Feb 25, 2019Phase 3 study in Chronic MigraineNCT03855137 · 778 enrolled · United States, Australia, Canada and more
  2. May 3, 2019Phase 3 study in Migraine DisordersNCT03939312 · 685 enrolled · United States
  3. Jun 16, 2020Phase 3 study in Chronic MigraineNCT04437433 · 186 enrolled · Japan
  4. Dec 21, 2020Phase 3 study in Episodic MigraineNCT04686136 · 596 enrolled · United States, Canada, Czechia and more
  5. Feb 2, 2021Phase 3 study in Episodic MigraineNCT04740827 · 315 enrolled · United States, Australia, Canada and more
  6. Mar 24, 2021Phase 1 study in Migraine DisordersNCT04818515 · 26 enrolled · United States
  7. Apr 1, 2021Phase 3 study in Migraine DisordersNCT04829747 · 3 enrolled · China
  8. Jan 19, 2022Phase 3 study in Migraine DisordersNCT05216263 · 75 enrolled · United States
  9. Feb 22, 2022Phase 4 study in Episodic MigraineNCT05264129 · 263 enrolled · United States
  10. Jan 24, 20232 phase 3 studiesNCT05707949, NCT05711394
  11. May 8, 2023Phase 3 study in Migraine DisordersNCT05861427 · 524 enrolled · Japan
  12. May 30, 2023Phase 1 study in Healthy VolunteersNCT05892757 · 24 enrolled · United States
  13. Jan 28, 2024Phase 3 study in Migraine DisordersNCT06241313 · 2,158 enrolled · Belgium, China, Czechia and more
  14. Jan 29, 20252 phase 3 studiesNCT06806293, NCT06810505

Ahead

  1. Mar 2028Primary completion: phase 3 study in Episodic MigraineNCT05711394
  2. Mar 2031Primary completion: phase 3 study in Migraine DisordersNCT06810505
  3. Apr 2032Primary completion: phase 3 study in Migraine ProphylaxisNCT05707949

TargetBeta

“An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the preventive treatment of migraines”NCIt, by rule
“Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ubrogepantruleAbbViephase 413
zavegepantrulePfizerphase 313

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06810505Migraine Disorders · United States, Canada, Denmark and more3RecruitingMar 2031420
NCT06806293Menstrual Migraine (MM) · China, Czechia, Germany and more3Active, not recruitingJun 29, 2026468
NCT06241313Migraine Disorders · Belgium, China, Czechia and more3CompletedJul 7, 20252,158
NCT05892757Healthy Volunteers · United States1CompletedFeb 22, 202424
NCT05861427Migraine Disorders · Japan3CompletedMar 1, 2025524
NCT05711394Episodic Migraine · United States, Belgium, Canada and more3RecruitingMar 2028450
NCT05707949Migraine Prophylaxis · United States, Belgium, Canada and more3By invitationApr 2032650
NCT05264129Episodic Migraine · United States4CompletedApr 4, 2023263
NCT05216263Migraine Disorders · United States3CompletedMay 2, 202575
NCT04829747Migraine Disorders · China3CompletedJan 20, 20223
NCT04818515Migraine Disorders · United States1CompletedJun 18, 202126
NCT04740827Episodic Migraine · United States, Australia, Canada and more3CompletedAug 4, 2022315
NCT04686136Episodic Migraine · United States, Canada, Czechia and more3CompletedOct 20, 2025596
NCT04437433Chronic Migraine · Japan3CompletedJun 11, 2024186
NCT03939312Migraine Disorders · United States3CompletedMar 31, 2021685
NCT03855137Chronic Migraine · United States, Australia, Canada and more3CompletedJan 20, 2022778
NCT03777059Migraine Disorders · United States3CompletedJun 19, 2020910
NCT03700320Episodic Migraine · United States3CompletedMay 21, 2020744
NCT02848326Migraine Disorders · United States3CompletedApr 2, 2018834

How it is read

Names in the registry

  • “Atogepant”, 15 entries
  • “Atogepant 60 mg”, 4 entries
  • “Atogepant 30 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.